Last reviewed · How we verify
Sorafenib (SOR)
Sorafenib is a multi-kinase inhibitor that blocks several protein kinases involved in tumor cell proliferation and angiogenesis, including RAF, VEGFR, and PDGFR.
Sorafenib is a multi-kinase inhibitor that blocks several protein kinases involved in tumor cell proliferation and angiogenesis, including RAF, VEGFR, and PDGFR. Used for Hepatocellular carcinoma, Renal cell carcinoma, Differentiated thyroid cancer (radioactive iodine-refractory).
At a glance
| Generic name | Sorafenib (SOR) |
|---|---|
| Also known as | Nexavar |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Drug class | Multi-kinase inhibitor; RAF/VEGFR/PDGFR inhibitor |
| Target | RAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Sorafenib inhibits both intracellular (RAF/MEK/ERK) and receptor tyrosine kinases (VEGFR-2, VEGFR-3, PDGFR-β) that are critical for tumor growth and blood vessel formation. By targeting these pathways, it reduces tumor cell proliferation and impairs the tumor's ability to develop new blood vessels (angiogenesis), thereby limiting nutrient supply to cancer cells.
Approved indications
- Hepatocellular carcinoma
- Renal cell carcinoma
- Differentiated thyroid cancer (radioactive iodine-refractory)
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Rash
- Fatigue
- Hypertension
- Nausea
- Alopecia
- Bleeding
Key clinical trials
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (PHASE2)
- Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer (PHASE2)
- Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
- Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis (PHASE2)
- Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
- TACE Combined With Sorafenib and Tislelizumab for Advanced HCC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sorafenib (SOR) CI brief — competitive landscape report
- Sorafenib (SOR) updates RSS · CI watch RSS
- The University of Texas Health Science Center at San Antonio portfolio CI